Question · Panya answer

What is the actual difference between Mounjaro and Zepbound?

Both are tirzepatide made by Eli Lilly. Same molecule, same supply chain, same factory. Mounjaro is the brand for type-2 diabetes; Zepbound is the brand for chronic weight management. Different labelled indication, different insurance posture, otherwise functionally identical.

Last reviewed · Panya.health editorial

The molecule is the same

Tirzepatide is the active ingredient in both. Lilly manufactures both at the same facilities. There is no clinical reason to prefer one over the other based on the molecule itself. The KwikPen device is identical. Storage requirements are identical. The drug interactions, side effects, and contraindications are identical.

The label is what differs

FDA approved Mounjaro for type-2 diabetes in May 2022. Zepbound followed for chronic weight management in November 2023. The labelled indication is what insurance reads. If you have T2D, your insurance is more likely to cover Mounjaro. If you do not have T2D but qualify on BMI, Zepbound is the on-label path. Outside the US, Mounjaro is often the only branded version available because Zepbound has not launched everywhere yet.

Why this matters for cost

In the US, Lilly's direct-to-consumer pharmacy LillyDirect prices the Zepbound vial form at meaningfully lower than Mounjaro pens for cash-pay patients. In Asia and the Middle East the only available form is usually Mounjaro because the Zepbound launch lagged. If you are in Bangkok, Singapore, Dubai, the bottle-and-pen on the pharmacy shelf is Mounjaro. Identical molecule, do not pay a premium chasing one brand over the other.

Your specific match

The answer for your situation.

The answer above is the general case. The match for your specific profile, region, budget, and urgency comes from our 2-minute quiz. One email, your match, no list.

We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.